Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2026-02-23 @ 4:54 AM
Study NCT ID:
NCT02362594
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-15
First Post:
2015-02-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-07-16
Start Date Type:
ACTUAL
Primary Completion Date:
2018-01-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2015-02-09
First Submit QC Date:
None
Study First Post Date:
2015-02-13
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-12-10
Results First Submit QC Date:
None
Results First Post Date:
2019-01-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-03
Last Update Post Date:
2025-10-15
Last Update Post Date Type:
ESTIMATED